Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE
Document Type and Number:
WIPO Patent Application WO/2024/051683
Kind Code:
A1
Abstract:
Disclosed is a pharmaceutical composition for inhalation, comprising a long-acting β2 agonist and a long-acting muscarinic antagonist. The long-acting β2 agonist may comprise olodaterol; alternatively, the long-acting β2 agonist may comprise arformoterol, and the pH value of the composition may be 3.5-5.5; alternatively, the long-acting β2 agonist may comprise indacaterol, and the pH value of the composition may be 2.5-4.5; alternatively, the long-acting muscarinic antagonist may comprise revefenacin, and the pH value of the composition may be 3.5-5.5; alternatively, the long-acting muscarinic antagonist may comprise glycopyrronium bromide, and the pH value of the composition may be 2.5-4.5; alternatively, the long-acting muscarinic antagonist comprises tiotropium bromide, and the pH value of the composition is 2.0-4.0. Disclosed is use of the pharmaceutical composition in the preparation of a pharmaceutical composition for inhalation for preventing or treating a respiratory disease such as asthma and chronic obstructive pulmonary disease.

Inventors:
LEE JUNNING (CN)
LIU YANG (CN)
Application Number:
PCT/CN2023/116985
Publication Date:
March 14, 2024
Filing Date:
September 05, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
LEXENPHARM SUZHOU LTD (CN)
International Classes:
A61K31/538; A61K31/167; A61K31/46; A61K31/4704; A61P11/00; A61P11/08
Domestic Patent References:
WO2020148638A12020-07-23
WO2020217116A22020-10-29
WO2014016548A22014-01-30
WO2019142214A12019-07-25
WO2021068961A12021-04-15
Foreign References:
US20210322311A12021-10-21
US20150157567A12015-06-11
CN106943350A2017-07-14
CN103784449A2014-05-14
US20200215051A12020-07-09
CN111481550A2020-08-04
CN105125542A2015-12-09
Attorney, Agent or Firm:
BEIJING WANHUIDA LAW FIRM (CN)
Download PDF: